Matches in SemOpenAlex for { <https://semopenalex.org/work/W609527633> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W609527633 abstract "OBJECTIVE: The objective of this preliminary analysis is to provide information of Qol and persistence with treatment BACKGROUND: Many registries provided real word information about quality of life (Qol) and persistence with oral treatments in multiple sclerosis, no information exists in Argentina. The aim of the Argentinean registry of patients treated with fingolimod (REAL) is to prospectively study the safety, effectiveness, Qol and persistence with fingolimod in Argentina DESIGN/METHODS: REAL is a prospective, 2-year, open-label study enrolling 200 patients with RRMS from 25 centres across Argentina. Qol was evaluated every three months by MusiQol scale (validated in Spanish). Persistence was defined as an absence of a gap in exposure to fingolimod of at least 30 days for any reason. RESULTS: A total of 92 patients were included. Mean age 37 ± 7 years. A total of 78.3[percnt] of included patients were previously treated for MS. Mean time under fingolimod treatment was 10 ± 6 months (range 1-25 months). The overall increment of Qol was significant y during the follow-up period (baseline index 52.5 vs. 62.5 p <0.001) but mainly this was observed in patients previously treated with other disease modifying drugs (baseline index 48.7 vs. 58.6 p<0.001) rather than in naive patients (baseline index 63.5 vs. 66.6 p 0.22). Eight patients dropped out during the follow-up period. Persistence with fingolimod treatment was observed in 91.3[percnt] of patients after a 10-month period . CONCLUSIONS: In this cohort of 92 patients a significant increase in Qol was observed, mainly in patients previously treated with others disease modifying drugs, suggesting an additional benefit of fingolimod as a second-line treatment. Additionally, a high persistence with therapy was observed in patients on fingolimod treatment during the follow-up period, emphasizing the importance of the adherence to and persistence with the treatment in the efficacy of fingolimod. Study Supported by: Disclosure: Dr. Kuperman has received personal compensation for activities with Novartis as an employee." @default.
- W609527633 created "2016-06-24" @default.
- W609527633 creator A5018670559 @default.
- W609527633 date "2015-04-06" @default.
- W609527633 modified "2023-09-25" @default.
- W609527633 title "Interim analysis II from REAL Study: Quality of life and persistence with fingolimod treatment in relapsing remitting multiple sclerosis patients in Argentina (P3.255)" @default.
- W609527633 hasPublicationYear "2015" @default.
- W609527633 type Work @default.
- W609527633 sameAs 609527633 @default.
- W609527633 citedByCount "0" @default.
- W609527633 crossrefType "journal-article" @default.
- W609527633 hasAuthorship W609527633A5018670559 @default.
- W609527633 hasConcept C126322002 @default.
- W609527633 hasConcept C127413603 @default.
- W609527633 hasConcept C159110408 @default.
- W609527633 hasConcept C187212893 @default.
- W609527633 hasConcept C187320778 @default.
- W609527633 hasConcept C188816634 @default.
- W609527633 hasConcept C203014093 @default.
- W609527633 hasConcept C2776036978 @default.
- W609527633 hasConcept C2779134260 @default.
- W609527633 hasConcept C2779951463 @default.
- W609527633 hasConcept C2780640218 @default.
- W609527633 hasConcept C2780892749 @default.
- W609527633 hasConcept C2781009140 @default.
- W609527633 hasConcept C3020694758 @default.
- W609527633 hasConcept C535046627 @default.
- W609527633 hasConcept C61943457 @default.
- W609527633 hasConcept C71924100 @default.
- W609527633 hasConcept C72563966 @default.
- W609527633 hasConceptScore W609527633C126322002 @default.
- W609527633 hasConceptScore W609527633C127413603 @default.
- W609527633 hasConceptScore W609527633C159110408 @default.
- W609527633 hasConceptScore W609527633C187212893 @default.
- W609527633 hasConceptScore W609527633C187320778 @default.
- W609527633 hasConceptScore W609527633C188816634 @default.
- W609527633 hasConceptScore W609527633C203014093 @default.
- W609527633 hasConceptScore W609527633C2776036978 @default.
- W609527633 hasConceptScore W609527633C2779134260 @default.
- W609527633 hasConceptScore W609527633C2779951463 @default.
- W609527633 hasConceptScore W609527633C2780640218 @default.
- W609527633 hasConceptScore W609527633C2780892749 @default.
- W609527633 hasConceptScore W609527633C2781009140 @default.
- W609527633 hasConceptScore W609527633C3020694758 @default.
- W609527633 hasConceptScore W609527633C535046627 @default.
- W609527633 hasConceptScore W609527633C61943457 @default.
- W609527633 hasConceptScore W609527633C71924100 @default.
- W609527633 hasConceptScore W609527633C72563966 @default.
- W609527633 hasLocation W6095276331 @default.
- W609527633 hasOpenAccess W609527633 @default.
- W609527633 hasPrimaryLocation W6095276331 @default.
- W609527633 hasVolume "84" @default.
- W609527633 isParatext "false" @default.
- W609527633 isRetracted "false" @default.
- W609527633 magId "609527633" @default.
- W609527633 workType "article" @default.